Expiration date: 01/2022 

Structure and Composition: 

Injection 

1ml contains deproteinized dialysate from the blood of healthy dairy calves standardized chemically and biologically (on dry basis) 42.5 mg

Excipients: Water for injection - up to 1 ml

in 2 ml ampoules in a box of 25 vials or ampoules of 5 ml and 10 in box 5 vials.

gel

1g contains deproteinized dialysate from the blood of healthy dairy calves, chemically and biologically standardized (in terms of dry matter) 4.15 mg

preservatives: methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216)

Other ingredients: calcium carboxymethylcellulose, sodium lactate propyleneglycol water for injection

in tubes of 20 g in a box 1 tube.

Ointment

1g contains deproteinized dialysate from the blood of healthy dairy calves, chemically and biologically standardized (in terms of dry matter) 2.07 mg

preservatives: methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216)

Excipients: cetyl alcohol, cholesterol white petrolatum water for injection

in tubes of 20 g in a box 1 tube.

Description pharmaceutical form:

Solcoseryl gel: a homogeneous, virtually colorless, transparent gel solid consistency.

Solcoseryl ointment: uniform, fat, easy to distribute weight from white to yellowish.

Pharmachologic effect:

The drug is Solcoseryl deproteined gemodializat containing a wide range of low-molecular components of cell mass and blood serum of dairy calves with a molecular weight of the D 5000, the properties of which are currently only partially studied chemical and pharmacological methods.

In in vitro tests, as well as in preclinical and clinical studies have found that Solkoseril:

  • Increases the reparative and regenerative processes
  • It helps to activate the aerobic metabolic processes and oxidative phosphorylation
  • Increases oxygen consumption in vitro and stimulates the transport of glucose into cells in hypoxic conditions and metabolically depleted cells
  • Increases collagen synthesis (in vitro)
  • Stimulates cell migration and proliferation (in vitro).

Solcoseryl gel does not contain fat as an auxiliary component, thereby easily washed off. It promotes the formation of granulation tissue, and elimination of fluid.

Since the appearance of fresh granulation and drying wound recommended Solcoseryl ointment containing as an auxiliary component fats and forming a protective film on the wound surface.

Pharmacokinetics:

Carrying on absorption, distribution and excretion of the drug using standard pharmacokinetic techniques is not possible because the active ingredient of the drug (deproteined gemodializat) has pharmacodynamic effects characteristic of molecules with different physical and chemical properties.

Testimony:

Solcoseryl injection.

  • Occlusive peripheral arterial disease in stages III-IV for Fontaine in patients with contraindication / intolerance to other drugs
  • chronic venous insufficiency, accompanied by trophic disorders (Ulcera cruris), in cases of persistent currents
  • disorders of cerebral metabolism and blood flow (ischemic and hemorrhagic stroke, traumatic brain injury).
  • Solcoseryl gel, ointment.

Minor damage (bruises, scratches, cuts).

Burns 1 and 2 degrees (sunburn, thermal burns).

Frostbite.

It is difficult to heal wounds (including trophic ulcers and bed sores).

Contraindications:

Solcoseryl injection.

Installed hypersensitivity to bovine blood dialysate

Solcoseryl injection contains as parahydroxybenzoic acid derivatives (E216 and E218), used as a preservative, and - trace amounts of free benzoic acid (E210), the drug should not be used in the presence of an allergic reaction to components listed

Safety data application Solcoseryl injection in children are not available, so the drug should not be administered to children under 18 years of age

Solcoseryl injection should not be mixed when administered with other drugs, with the exception of isotonic sodium chloride solution and 5% glucose solution.

Solcoseryl gel, ointment.

Hypersensitivity to one of the components of the preparation.

Be wary - if predisposition to allergic reactions.

Application of pregnancy and breastfeeding:

Despite a lack of data on the teratogenicity Solcoseryl the drug should be used with caution during pregnancy. Data on the safety Solcoseryl injection during lactation are not available. If necessary, use of the drug is recommended to stop breast-feeding.

Side effect:

Solcoseryl injection.

In rare cases can develop an allergic reaction (hives, redness and swelling at the injection site, fever). In this case, you must stop using the product and assign an expected treatment.

Solcoseryl gel, ointment.

In rare cases, the site of application Solcoseryl may develop allergic reactions such as hives, dermatitis edge. In this case, you must stop using the product and seek medical advice.

The site of application Solcoseryl gel may experience a brief burning sensation. If burning a long time does not pass, should renounce the use of Solcoseryl gel.

Drug Interactions:

Solcoseryl injection should not be mixed when administered with other drugs, especially - with phyto extracts.

Pharmaceutical Solcoseryl incompatibilities established as a solution for injection parenteral forms:

extract of Ginkgo biloba,

naftidrofuryl

bentsiklana fumarate.

As solutions for the dilution of Solcoseryl injection should be used only isotonic sodium chloride solution, and 5% glucose solution.

Solcoseryl interaction with other topical drugs are not established.

Dosage and administration:

Solcoseryl injection: in / in or / m.

In the treatment of occlusive peripheral arterial disease in stages III-IV on Fontaine - in / 20 ml daily. Perhaps intravenous drip in isotonic sodium chloride solution or 5% glucose solution. Duration of treatment - up to 4 weeks and is determined by the clinical picture of the disease.

In the treatment of chronic venous insufficiency, accompanied by trophic disorders (Ulcera cruris) - / v, 10 ml, 3 times a week. Duration of treatment - no more than 4 weeks and is determined by the clinical picture of the disease. An important additional measures aimed at the prevention of peripheral "venous" edema is overlaying a pressure bandage using an elastic bandage.

If you have a local trophic disorders of tissues recommended simultaneous drug therapy Solcoseryl jelly and then Solcoseryl ointment.

In the treatment of ischemic and hemorrhagic strokes in severe and very severe, as the primary rate - in / at 10 or 20 ml, respectively, every day for 10 days. Upon completion of the primary rate - a / m or / 2 ml for 30 days.

Traumatic brain injury (brain contusion, severe) - I / 1000 mg daily for 5 days.

If the I / drug administration impossible, the drug may be administered in / m, typically 2 ml undiluted day.

The on / in the application of undiluted product must be administered slowly, because it is a hypertonic solution.

Solcoseryl gel, ointment: topical.

Applied directly on the wound surface after preliminary cleansing wounds with a disinfecting solution.

Before the treatment of venous ulcers, as well as in cases of purulent wound infections requires pre-surgical treatment.

Solcoseryl gel is applied to fresh wounds, wounds with wet detachable on ulcers with signs soak - thin layer on the cleaned wound 2-3 times a day. Sites started epithelialization solkoserilom be lubricated with ointment. The use of gel Solcoseryl continues until a pronounced granulation tissue over the damaged surface of the skin and drying wounds.

Solcoseryl ointment is used primarily for the treatment of dry (nemoknuschih) wounds.

Solcoseryl ointment applied in a thin layer on clean the wound 1-2 times a day, can be used under bandages. The course of treatment solkoserilom ointment continues until complete healing of the wound, it epithelialization and the formation of an elastic scar tissue.

simultaneous use of parenteral forms Solcoseryl recommended for the treatment of severe trophic lesions of the skin and soft tissues.

Overdose:

For information about the effects of overdose Solcoseryl (injection, gel, ointment) are absent.

Special instructions:

Solcoseryl (gel, ointment) should not be applied to a contaminated wound as it contains not contain antimicrobial components.

Application Solcoseryl, like all other drugs, it is undesirable during pregnancy and breastfeeding, and is possible only when absolutely necessary and under medical supervision.

In case of pain, redness of the skin near the site of application Solcoseryl, highlight the secretion from the wound, fever is an urgent need to consult a doctor.

If the application of Solcoseryl not observed the healing of the affected area for 2-3 weeks, you should see a doctor.

Write a review

Note: HTML is not translated!
    Bad           Good

Solcoseryl


Available Options